Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.9968 | 1 | 0.5 |
Loa Loa (eye worm) | PAN domain-containing protein | 0.0062 | 0 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.9968 | 1 | 1 |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.9968 | 1 | 1 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.9968 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.9968 | 1 | 0.5 |
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.9968 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.9968 | 1 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.3892 | 0.3867 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.9968 | 1 | 1 |
Leishmania major | dihydroorotate dehydrogenase | 0.9968 | 1 | 0.5 |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.9968 | 1 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0957 | 0.0904 | 0.0904 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.9968 | 1 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.9968 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Brugia malayi | Zinc finger, C2H2 type family protein | 0.3892 | 0.3867 | 0.3867 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Loa Loa (eye worm) | PAN domain-containing protein | 0.0062 | 0 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Entamoeba histolytica | dihydropyrimidine dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.9968 | 1 | 0.5 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.3892 | 0.3867 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Loa Loa (eye worm) | PAN domain-containing protein | 0.0062 | 0 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0957 | 0.0904 | 0.0904 |
Loa Loa (eye worm) | PAN domain-containing protein | 0.0062 | 0 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Trichomonas vaginalis | dihydropyrimidine dehydrogenase, putative | 0.3892 | 0.3867 | 0.5 |
Loa Loa (eye worm) | PAN domain-containing protein | 0.0062 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.3892 | 0.3867 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.9968 | 1 | 1 |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.3892 | 0.3867 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0062 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ID50 (functional) | = 0.6 ug ml-1 | Inhibitory effect on the proliferation of human T-lymphoblast cells (Molt-4F) | ChEMBL. | 1324318 |
ID50 (functional) | = 0.77 ug ml-1 | Inhibitory effect on the proliferation of human T-lymphocyte (MT-4) | ChEMBL. | 1324318 |
ID50 (functional) | = 1.24 ug ml-1 | Inhibitory effect on the proliferation of murine leukemia cells (L1210) | ChEMBL. | 1324318 |
ID50 (functional) | = 1.4 ug ml-1 | Inhibitory effect on the proliferation of murine leukemia cells (L1210) | ChEMBL. | 1324318 |
ID50 (functional) | = 1.54 ug ml-1 | Inhibitory effect on the proliferation of human T-lymphoblast cells (Molt-4F) | ChEMBL. | 1324318 |
ID50 (functional) | = 3.53 ug ml-1 | Inhibitory effect on the proliferation of human T-lymphocyte (MT-4) | ChEMBL. | 1324318 |
MCC (functional) | > 4 ug ml-1 | Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MCC (functional) | = 8 ug ml-1 | Compound was evaluated in MDCK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MCC (functional) | > 10 ug ml-1 | Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MCC (functional) | = 10 ug ml-1 | Evaluation in PRK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MCC (functional) | = 40 ug ml-1 | Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MCC (functional) | = 40 ug ml-1 | Compound was evaluated in MDCK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MCC (functional) | = 40 ug ml-1 | Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology | ChEMBL. | 1324318 |
MIC (functional) | > 1 ug ml-1 | Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 1 ug ml-1 | Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 1 ug ml-1 | Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 1.6 ug ml-1 | Compound was evaluated for antiviral activity against respiratory syncitial virus (long) in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 1.6 ug ml-1 | Concentration required to reduce influenza virus A (ishikawa) induced cytopathogenicity by 50% | ChEMBL. | 1324318 |
MIC (functional) | > 1.6 ug ml-1 | Concentration required to reduce influenza virus B (singapore) induced cytopathogenicity by 50% | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-1(F) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-2(196) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-2(Lyons) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-1(McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 2 ug ml-1 | Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 3 ug ml-1 | Compound was evaluated for antiviral activity against respiratory syncitial virus (long) in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 3 ug ml-1 | Concentration required to reduce influenza virus A (ishikawa) induced cytopathogenicity by 50% | ChEMBL. | 1324318 |
MIC (functional) | = 3 ug ml-1 | Concentration required to reduce influenza virus B (singapore) induced cytopathogenicity by 50% | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against reo virus-1 in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against Sindbis virus in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against forest virus in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-1(McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 4 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 7 ug ml-1 | Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 7 ug ml-1 | Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 7 ug ml-1 | Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 7 ug ml-1 | Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 10 ug ml-1 | Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | > 10 ug ml-1 | Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 10 ug ml-1 | Evaluation for antiviral activity against forest virus in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 20 ug ml-1 | Evaluation for antiviral activity against reo virus-1 in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
MIC (functional) | = 20 ug ml-1 | Evaluation for antiviral activity against Sindbis virus in Vero cell cultures(Concentration required to reduce virus-induced cytopathogenicity by 50%) | ChEMBL. | 1324318 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.